Cargando…

Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis

BACKGROUND: Peripheral neuropathy (PN) is a common consequence of multiple myeloma (MM) among those commonly treated with older-generation proteasome inhibitors (PIs). In this study, we evaluated the economic burden attributable to PN among MM patients in real-world practice settings in the US. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Xue, Wilson, Kathleen L., Kagan, Jerry, Panjabi, Sumeet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444783/ https://www.ncbi.nlm.nih.gov/pubmed/30967926 http://dx.doi.org/10.1177/2040620719839025

Ejemplares similares

Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US
por: Fonseca, Rafael, et al.
Publicado: (2021)

The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma
por: MacEwan, Joanna P, et al.
Publicado: (2021)

A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting
por: Rifkin, Robert M., et al.
Publicado: (2019)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

The Positive Effects of One-Hour Intravenous Administration of Bortezomib on Peripheral Neuropathy in Multiple Myeloma Patients
por: Jung, Joo Young, et al.
Publicado: (2014)

Development and Validation of an Algorithm to Identify Patients with Multiple Myeloma Using Administrative Claims Data
por: Princic, Nicole, et al.
Publicado: (2016)

Managing treatment-related peripheral neuropathy in patients with multiple myeloma
por: Grammatico, Sara, et al.
Publicado: (2016)

Healthcare Utilization and Direct Costs in Patients with Ankylosing Spondylitis Using a Large US Administrative Claims Database
por: Walsh, Jessica A., et al.
Publicado: (2018)

Disease burden and cost of hidradenitis suppurativa: a retrospective examination of US administrative claims data
por: Marvel, Jessica, et al.
Publicado: (2019)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma
por: Han, Xiaoyan, et al.
Publicado: (2017)

A claims‐based, machine‐learning algorithm to identify patients with pulmonary arterial hypertension
por: Hyde, Bethany, et al.
Publicado: (2023)

Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy
por: Merola, David, et al.
Publicado: (2018)

Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study
por: George, Marjorie Patricia, et al.
Publicado: (2023)

Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis
por: Kocaata, Zeki, et al.
Publicado: (2022)

Estimation of minimally important differences and responder definitions for EORTC QLQ‐MY20 scores in multiple myeloma patients
por: Sully, Kate, et al.
Publicado: (2019)

Multiple Myeloma and Vasculitic Neuropathy: An Unusual Presentation
por: Simkhada, Nabin, et al.
Publicado: (2021)

Clinical and Cost Burden of Primary Sjögren’s Syndrome: Descriptive Analysis Using a US Administrative Claims Database
por: Perera, Sue, et al.
Publicado: (2018)

Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients
por: Dong, Mengmeng, et al.
Publicado: (2022)

Effectiveness of a vitamin D regimen in deficient multiple myeloma patients and its effect on peripheral neuropathy
por: Oortgiesen, Berdien E., et al.
Publicado: (2023)

Repetitive transcranial magnetic stimulation for chemotherapy-induced peripheral neuropathy in multiple myeloma: A pilot study
por: Yan, Zhenzhuang, et al.
Publicado: (2023)

Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis
por: Fox, Robert J., et al.
Publicado: (2022)

Phase-Specific and Lifetime Costs of Multiple Myeloma Among Older Adults in the US
por: Bhattacharya, Kaustuv, et al.
Publicado: (2021)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States
por: Ogbomo, Adesuwa, et al.
Publicado: (2022)

Analysis of dementia in the US population using Medicare claims: Insights from linked survey and administrative claims data
por: Chen, Yi, et al.
Publicado: (2019)

Peripheral neuropathy in patients with multiple sclerosis
por: Khan, Adnan, et al.
Publicado: (2018)

Development and Validation of an Algorithm to Identify Endometrial Adenocarcinoma in US Administrative Claims Data
por: Esposito, D. B., et al.
Publicado: (2019)

Peripheral Neuropathy Secondary to Ertapenem Administration for Treatment of Infectious Endocarditis
por: Buckman, Patrick J, et al.
Publicado: (2023)

Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients
por: Mahmoudpour, Seyed Hamidreza, et al.
Publicado: (2018)

Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and α-Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data
por: Maschio, Marta, et al.
Publicado: (2018)

High prevalence of peripheral neuropathy in multiple myeloma patients and the impact of vitamin D levels, a cross-sectional study
por: Oortgiesen, B. E., et al.
Publicado: (2021)

Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study
por: Biran, Noa, et al.
Publicado: (2020)

Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US
por: Jagannath, Sundar, et al.
Publicado: (2021)

Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set
por: Walsh, Jessica A., et al.
Publicado: (2018)

Healthcare Resource Utilization and Costs in Celiac Disease: A US Claims Analysis
por: Cappell, Katherine, et al.
Publicado: (2020)

Descriptive Analysis of the Direct Medical Costs of Multiple Sclerosis in 2004 Using Administrative Claims in a Large Nationwide Database
por: Prescott, Jeff D., et al.
Publicado: (2007)

Identification of pregnancies and infants within a US commercial healthcare administrative claims database
por: Bertoia, Monica L., et al.
Publicado: (2022)

Diagnostic and cost utility of whole exome sequencing in peripheral neuropathy
por: Walsh, Maie, et al.
Publicado: (2017)

The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution
por: Bonomo, Lauren, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b9f6r3mqrr0l447petcs5pfi2o